This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Jenny was still in college when she learned she had advanced Hodgkin lymphoma. Her mother researched immunotherapy clinical trial options and helped Jenny become her own patient advocate. She enrolled in a trial testing a combination of the anti-PD-1 checkpoint inhibitor nivolumab (Opdivo®) along with the antibody-drug conjugate brentuximab vedotin (Adcentris®).
Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).